Compare AbbVie Inc (ABBV) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Health Care Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Health Care Select Sector SPDR Fund trades at $162.94. The key difference: AbbVie Inc pays a 2.72% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| ABBV | XLV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $164.48 |
52-Week Low | $184.85 | $129.01 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
XLV trades at $162.06, down 1.03% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The healthcare ETF benefits from defensive sector positioning amid market volatility, with recent news highlighting healthcare as a safe haven during choppy markets. A dividend of $0.66 is scheduled for June 2026, providing income appeal.
Outlook remains positive given healthcare's defensive characteristics and innovation momentum in biotech and pharmaceuticals. Key risks include sector-specific regulatory pressures and patent cliff concerns for major holdings. Analyst sentiment leans bullish with technical support at $160 and resistance at $164.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
